Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temozolomide and Proton Chemoradiotherapy for High-Risk Soft Tissue Sarcomas
NCT00881595Phase 2Withdrawn
- Sponsor
- University of Florida
- Start
- Feb 2009
- Primary completion
- Nov 2012
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of temozolomide in soft tissue sarcoma (STS), sponsored by University of Florida. Primary endpoint: Treatment feasibility of neoadjuvant temozolomide-based proton chemoradiotherapy. Planned start Feb 2009; status: withdrawn.
02
Drugs
temozolomide
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT00881595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00881595.